Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival. - Wikidata - awgldk - TriplyDB

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.

http://www.wikidata.org/entity/Q37826751

about

Rapid COJEC versus standard induction therapies for high-risk neuroblastoma Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.Tumor histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive?Tumor histology during induction therapy in patients with high-risk neuroblastoma.

P2860

Q24187922-2B5B92D6-6106-4FB8-B205-70DD41259E9C Q39552426-6E0ABEC6-92A4-45E1-BEC0-D6F9124E5BA0 Q48279517-522B26CC-DC5A-4E9A-B048-F382F78F5373 Q53199350-D8008C8F-E456-4E20-90D5-043F23955792

P2860

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.

http://www.wikidata.org/entity/Q37826751

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en-gb

Percentage tumor necrosis foll ...... MYCN status but not survival.

@nl

type

label

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en-gb

Percentage tumor necrosis foll ...... MYCN status but not survival.

@nl

prefLabel

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en-gb

Percentage tumor necrosis foll ...... MYCN status but not survival.

@nl

P1433

Q37826751-114AC190-ED9D-4157-901F-C13900DE5975

P1476

Q37826751-9744C049-97F9-4F29-9E57-A63D843AA354

P2093

Q37826751-16BF8109-0132-45A2-B507-FB7BF75C6F43

Q37826751-1F444181-48D9-40D4-9083-1F288ABD7128

Q37826751-5675B3B9-03FD-4133-8D0D-2764812FE614

Q37826751-589F7678-4762-420A-ACB6-06D3396B5BBD

Q37826751-7C9BA399-19A1-4217-AFF7-C8AB11906662

Q37826751-D383375F-D784-410A-B65B-E60E3E1040CD

P2860

Q37826751-0B192661-EDB3-4D85-B9CE-218D0A0FF5F8

Q37826751-0B831DBE-2A56-465C-B6DD-5CC2C759EBC8

Q37826751-145445B0-FECC-4C12-BA82-BD7C0EA889CA

Q37826751-28DE8A24-171A-4520-B4B5-E4C95A309E34

Q37826751-35B31FE2-A5F7-4661-8385-F71527C549F5

Q37826751-38B03354-03A1-4553-A46E-3E603719A0C0

Q37826751-3FB8DB4D-AD70-47F5-B7F7-97D6447840E5

Q37826751-87E18662-45C8-4B38-8B88-5AC223A92560

Q37826751-8ED6F90D-CC62-4D2E-A62C-D397B1CC5E93

Q37826751-B6E49F77-B0C5-4EDA-A8CB-C97E4E863665

P304

Q37826751-834EC941-0027-48DF-8CDF-47EB1D54D925

P31

Q37826751-E05AC5F8-C0CC-496B-9767-7D36B396E914

P356

Q37826751-390B793A-A4E8-4A3C-A618-F1E542E9BB3A

P433

Q37826751-0A881572-B84F-44A9-8C0F-9BBF8A9B421B

P478

Q37826751-B9F63D8E-66C1-46F3-857C-592FDD628785

P50

Q37826751-91C55E04-D7D0-48EB-9CD9-8804351579ED

P577

Q37826751-0A748A2B-60DA-49ED-9B60-6C9208585942

P698

Q37826751-62795081-03C4-490B-88AF-E4CA0DC66D36

P921

Q37826751-95BD074F-00A2-4704-AC97-68B842083F67

P356

08880018.2010.526684

P1433

Pediatric Hematology and Oncology

P1476

Percentage tumor necrosis foll ...... MYCN status but not survival.

@en

P2093

Beverley Davies

http://www.w3.org/2001/XMLSchema#string

Deborah A Tweddle

http://www.w3.org/2001/XMLSchema#string

Katrina M Wood

http://www.w3.org/2001/XMLSchema#string

Leeai Chong

http://www.w3.org/2001/XMLSchema#string

Michael Cole

http://www.w3.org/2001/XMLSchema#string

Simon Bomken

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Histologic survey of neuroblastomas after intensive induction chemotherapy.

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.

p53 is a direct transcriptional target of MYCN in neuroblastoma

OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.

Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.

P304

106-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08880018.2010.526684

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Michael McDermott

P577

2011-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21214410

http://www.w3.org/2001/XMLSchema#string

P921